Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

DOI Web Site 10 Citations
  • David Devos
    Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France.
  • Caroline Moreau
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Jean Christophe Devedjian
    EA 1046, Lille Nord de France University, Lille, France.
  • Jérome Kluza
    Unit 837 Equipe 4 Inserm and Faculté de Médecine, Lille Nord de France University, Lille, France.
  • Maud Petrault
    Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France.
  • Charlotte Laloux
    Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France.
  • Aurélie Jonneaux
    Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France.
  • Gilles Ryckewaert
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Guillaume Garçon
    Department of Toxicology, Public Health and Environment, EA4483, Faculté des Sciences Pharmaceutiques et Biologiques de Lille, Lille, France.
  • Nathalie Rouaix
    Department of Molecular Biology, Lille Nord de France University, CHU Lille, Lille, France.
  • Alain Duhamel
    Department of Biostatistics, Lille Nord de France University, CHU Lille, Lille, France.
  • Patrice Jissendi
    Department Neuroradiology, Lille Nord de France University, CHU Lille, Lille, France.
  • Kathy Dujardin
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Florent Auger
    EA 1046, Lille Nord de France University, Lille, France.
  • Laura Ravasi
    EA 1046, Lille Nord de France University, Lille, France.
  • Lucie Hopes
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Guillaume Grolez
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Wance Firdaus
    Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France.
  • Bernard Sablonnière
    Department of Molecular Biology, Lille Nord de France University, CHU Lille, Lille, France.
  • Isabelle Strubi-Vuillaume
    Department of Molecular Biology, Lille Nord de France University, CHU Lille, Lille, France.
  • Noel Zahr
    Department of Pharmacology, APHP, Pitié-Salpêtrière Hospital, Paris, France.
  • Alain Destée
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Jean-Christophe Corvol
    INSERM, CR-ICM, UMRS975, CNRS UMR7225, UPMC, INSERM, CIC-9503, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France.
  • Dominik Pöltl
    Doerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Konstanz, Germany.
  • Marcel Leist
    Doerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Konstanz, Germany.
  • Christian Rose
    Department of Hematology, Hôpital Saint Vincent de Paul, Lille Nord de France University, Lille, France.
  • Luc Defebvre
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France.
  • Philippe Marchetti
    Unit 837 Equipe 4 Inserm and Faculté de Médecine, Lille Nord de France University, Lille, France.
  • Z. Ioav Cabantchik
    Della Pergola Chair, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel.
  • Régis Bordet
    Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France.

Journal

Citations (10)*help

See more

Details 詳細情報について

Report a problem

Back to top